Abstract
Purity-matched neoadjuvant gefitinib-treated EGFR-mutated NSCLC tumors undergo a glycolytic to oxidative phosphorylation metabolic switch. A, Top 5 enriched mSigDB “hallmark” gene pathways found in purity-matched neoadjuvant gefitinib or treatment-naïve tumors in GSEA. B, Average glycolytic or oxidative phosphorylation gene expression Z-scores in treatment-naïve vs. neoadjuvant gefitinib tumors. C, Purity-matched metabolic pathway map of differentially expressed glycolysis and oxidative phosphorylation reactions in treatment-naïve vs. neoadjuvant gefitinib tumors. D, GSEA of top 5 enriched mSigDB “hallmark” gene pathways found via DSP ROIs (PanCK+, CD3+, and CD68+ regions) in representative treatment-naïve vs. neoadjuvant gefitinib tumors. E, PanCK+ metabolic pathway map of differentially expressed glycolysis and oxidative phosphorylation reactions in representative treatment-naïve vs. neoadjuvant gefitinib tumors. FC, fold change; TCA, tricarboxylic acid.